Skip to main content
padlock icon - secure page this page is secure

Recent Developments of Thalidomide Derivatives Possessing Anti-Inflammatory Activity

Buy Article:

$68.00 + tax (Refund Policy)

Thalidomide (α-N-phthalimidoglutarimide) was a widely used drug in the late 1950s as a hypnotic/ sedative agent. Thalidomide was subsequently withdrawn from the market due to teratogenicity in the early 1960s. Surprisingly, even after the initial impact of the thalidomide disaster, the drug was still used in the therapy of many diseases, and research studies in the field of thalidomide derivatives have significantly increased because of its tumor necrosis factor (TNF-α) production regulating effect. Recently, novel thalidomide derivatives have been synthesized as anti-inflammatory lead -candidates. This review will summarize the recent development of thalidomide derivatives which possess antiinflammatory activity.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Phthalimide; TNF-α; TNF-α inhibitors; Thalidomide; anti-angiogenic effects; anti-inflammatory activity; autoimmune diseases; immunomodulatory

Document Type: Research Article

Publication date: March 1, 2010

More about this publication?
  • Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of new Anti-Inflammatory & Anti-Allergy Agents.

    Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in Anti-Inflammatory & Anti-Allergy Medicinal Chemistry.

    Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in Anti-Inflammatory & Anti-Allergy Agents drug discovery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more